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G9a (KMT1C, EHMT2) is a lysine methyltransferase (KMT) whose primary function is to 
di-methylate lysine 9 of histone H3 (H3K9me2). G9a-dependent H3K9me2 is associated 
with gene silencing and acts primarily through the recruitment of H3K9me2-binding 
proteins that prevent transcriptional activation. Gene repression via G9a-dependent 
H3K9me2 is critically required in embryonic stem (ES) cells for the development of cel-
lular lineages by repressing expression of pluripotency factors. In the immune system, 
lymphoid cells such as T cells and innate lymphoid cells (ILCs) can differentiate from a 
naïve state into one of several effector lineages that require both activating and repres-
sive mechanisms to maintain the correct gene expression program. Furthermore, the 
long-term immunity to re-infection is mediated by memory T cells, which also require 
specific gene expression and repression to maintain a quiescent state. In this review, 
we examine the molecular machinery of G9a-dependent functions, address the role of 
G9a in lymphoid cell differentiation and function, and identify potential functions of T cells 
and ILCs that may be controlled by G9a. Together, this review will highlight the dynamic 
nature of G9a-dependent H3K9me2 in the immune system and shed light on the nature 
of repressive epigenetic modifications in cellular lineage choice.
Keywords: G9a, T  cells, innate lymphoid cells, epigenetics, immunological memory, mouse models, infection, 
inflammation
The mammalian immune system is made up of a large number of cell types that have the ability to 
respond to external environmental cues and adopt a wide variety of cell fates. These lineage decisions 
are critical for the development of proper immune responses to pathogens as well as important 
for the resolution of inflammatory responses. Despite the importance of these cell fate decisions, 
the molecular mechanisms that control them are still not completely described nor understood. 
In addition to expression of cell lineage-specific master regulatory transcription factors (TFs) (1), 
the epigenetic landscape of the chromatin is emerging as a central control point in cellular lineage 
differentiation.
In the immune system, lymphoid cells such as B cells, T cells, and innate lymphoid cells (ILCs) 
have the capacity to respond to the external environment by modulating the expression of lineage-
specific factors that are critical for protective immunity to a wide variety of pathogens. For example, 
the description of CD4 T helper (Th) cell subsets by Mosmann and Coffman in 1986 has provided 
a fundamental framework for the division of labor mediated by lymphoid cells (2). Naive Th cells 
respond to signals from innate immune cells—primarily secreted cytokines—to differentiate into 
one of several ‘lineages’ that differ in the expression of TFs, cytokines, and cell surface molecules 
(3). For example, Th1 cells differentiate from naive Th cells in the presence of IL-12, express the TFs 
FiGURe 1 | The structure of G9a. G9a is a 1,253 amino acid protein that 
has several distinct domains including an N-terminal activation domain, 
glutamate-rich (23 consecutive Glu residues) and cysteine-rich regions of 
unknown function, eight ankyrin repeat units (binding of dimethylated lysine 
residues), and a C-terminal enzymatic SET domain.
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STAT4 and T-bet, leading to the production of IFN-γ. In contrast, 
IL-4 signaling promotes STAT6 and GATA3 expression in Th 
cells, resulting in IL-4- and IL-13-producing Th2 cells. In recent 
years, additional Th cell subsets have been identified that derive 
from a naïve precursor cell, which include Th17 cells (that express 
the TF RORγt and secrete IL-17A) and Treg cells (that express 
the TF FOXP3 and secrete TGF-β). More recently, ILCs that have 
similar patterns of differentiation and gene expression have been 
identified. Although the differentiation of ILCs appears to occur 
earlier than Th cells with ‘committed’ progenitors exiting the bone 
marrow (4), distinct ILC subsets that are closely related to Th1, 
Th2, and Th17 cells (ILC1s, ILC2s, and ILC3s, respectively) have 
been described. Strikingly, the TF expression patterns are highly 
conserved between Th cells and ILCs, suggesting that generalized 
molecular mechanisms control lymphoid cell differentiation and 
function. Understanding the molecular mechanisms of immune 
cell differentiation will provide the basis for development of new 
therapies to promote immunity to infection as well as prevent 
inflammatory diseases caused by dysregulated immune responses.
ePiGeNeTiC ReGULATiON OF GeNe 
eXPReSSiON
Epigenetic regulation encapsulates a wide range of mechanisms 
that can result in heritable changes in gene expression. From physi-
cal localization of genes within the nucleus to post-translational 
modifications of DNA and histones, epigenetic mechanisms can 
profoundly influence gene expression and alter cellular lineage 
development and function. The site-specific methylation and 
demethylation of CpG motifs in DNA by DNA methyltrans-
ferases (DNMTs) and the TET family of proteins is perhaps the 
best studied epigenetic mechanism that directly regulates gene 
expression (5). Although DNA methylation has been implicated 
in lymphoid cell responses (6–8), this review will focus on the 
posttranslational methylation of histones.
Regulation of gene expression by histone modifying enzymes 
is an important mechanism that regulates cellular development 
and differentiation. Histones can be modified posttranslationally 
by phosphorylation, acetylation, ubiquitination, sumoylation, 
and methylation (9). In particular, methylation of histone lysine 
residues is an important regulator of gene expression. Mixed line-
age leukemia-1 (MLL1)-dependent H3K4me3 (10) and enhancer 
of zeste homolog-2 (EZH2)-dependent H3K27me3 (11) are the 
best known modifications and are associated with gene expression 
and repression, respectively (12–14). Other histone-methylation 
sites have been shown to be critical as well, including H3K9, with 
G9a-dependent H3K9me2 and Suv39h1/2-mediated H3K9me3 
playing important roles in cell differentiation and function 
(15–18). Of these, H3K9me2 has been shown to modify euchro-
matin and dynamically regulate gene expression in differentiat-
ing cells.
In embryonic stem (ES) cells, it has been proposed that 
H3K9me2 marks increase across the genome as cells differentiate 
and acquire lineage specificity (19) although this is contentious 
(20). Specifically, H3K9me2 is found enriched at lineage non-
specific genes, suggesting that acquisition of H3K9me2 is critical 
for gene silencing during differentiation (21). However, there is 
very little known about the role of G9a in cells of the immune 
system. In lymphoid cells such as T cells and ILCs, it is clear that 
G9a-dependent H3K9me2 is critical for cellular differentiation 
and function, although the mechanisms differ from ES cells. In 
this review, we focus on the role of the histone lysine methyl-
transferase G9a in lymphoid cell responses in health and disease.
G9a iS ReQUiReD FOR DiMeTHYLATiON 
OF H3K9
G9a (Ehmt2) was first identified as a gene located in the major 
histocompatibility complex (MHC) locus in mice and human 
leukocyte antigen (HLA) locus in humans and was also called 
HLA-B-associated transcript 8 (BAT8) (22–25). The Ehmt2 gene 
is located in the ~700  kb (mouse)/~1.1  Mb (human) MHC/
HLA Class III region that contains over 60 genes (26) including 
cytokines (TNF-α and TNF-β), complement proteins C2 and C4, 
heat shock proteins (HSP70), and enzymes (steroid 21-hydroxy-
lase Cyp21). The Ehmt2 gene is made up of 28 exons that code for 
a 1,263 amino acid protein. A splice form lacking exon 10 that 
codes for 34 amino acids has also been identified, although the 
functional significance is still unknown (24).
The related protein G9a-like protein (GLP, EHMT1) whose 
gene is not located in the MHC/HLA locus forms a heterodimer 
with G9a in vivo and is critically required for the H3K9me2 meth-
ylation activity (27). Genetic deletion of either protein results 
in a significant reduction in H3K9me2, suggesting that both 
subunits are essential to the enzymatic activity (28). Mutation 
of the active sites has shown that the methyltransferase activity 
of G9a plays a larger role in H3K9me2 methylation in vivo (29). 
However, global gene expression analysis of neurons of mice with 
targeted deletions of either G9a or GLP identified differences that 
may be due to differential requirement of each subunit in gene-
specific expression (30). Further, loss of GLP is associated with 
Kleefstra Syndrome, a rare genetic disease that is characterized by 
intellectual disability and other social and physical impairments 
(31). There has been no analysis of the function of immune cells 
in Kleefstra Syndrome patients. Thus, although GLP may play a 
specific role in regulation of gene expression, it remains to be 
directly tested.
G9a is a 1,263 amino acid protein with several distinct 
domains (Figure 1). G9a does not contain a DNA-binding domain 
and must rely on cofactors for its localization to specific genes. 
Functionally, the C-terminal SET domain contains the lysine 
methyltrans ferase activity that defines the major function of this 
family of pro teins. The SET domain of G9a is able to mono- and 
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dimethylate H3K9 but is less efficient in mediating trimethylation 
(32). Consistent with this, deletion of G9a leads to a global reduc-
tion in H3K9me2 while H3K9me3 is largely unaffected (18, 28). 
Unlike other members of the SET domain family, G9a also has 
unique domains that provide additional functions. First, G9a has 
a series of eight 33-amino acid repeats that have homology to the 
ankyrin repeat domain of Drosophila Notch (25). This region was 
further shown to act as a domain that could specifically bind to 
dimethylated lysine residues, providing a protein that can not only 
generate a specific posttranslational modification but also bind to 
that modification (33). Interestingly, although the ankyrin repeats 
of G9a have an affinity for H3K9me2, GLP binds to H3K9me1 
with higher affinity (33) and mice that carry a knock in of G9a 
with non-functional ankyrin repeats develop normally while 
mice with a mutated GLP have severe developmental defects 
resulting in perinatal lethality (34). These results further demon-
strate that G9a and GLP have some non-overlapping roles in vivo. 
G9a also has a stretch of 25 glutamic acid residues as well as a 
Cysteine-rich region, whose functions remain unknown.
Although G9a has predominantly been studied in the context 
of gene repression via its methyltransferase activity on histones, 
it is clear that G9a also has a role in gene activation under certain 
conditions (35–37), which is methyltransferase-independent (dis-
cussed below). This function has been mapped to the N-terminus 
of the protein as the first 280 amino acids are sufficient to promote 
gene expression by acting as a scaffold to recruit transcriptional 
coactivators such as CARM1 and p300 (36, 38). Thus, G9a is a 
complex protein that is involved in gene repression and activation 
through distinct mechanisms.
G9a iS THe MAJOR H3K9 
DiMeTHYLTRANSFeRASe
G9a is the enzyme that is responsible for the dimethylation of 
H3K9, a hallmark of silenced euchromatin (18, 28, 39–41). 
H3K9me2 acts as a binding site for heterochromatin protein 1 
(HP1) that recruits transcriptional repressors to prevent gene 
activation (42). Although H3K9me2 is the main product of G9a- 
dependent methylation, the G9a/GLP complex has also been 
described to methylate H1 (43, 44) and contributes to the meth-
ylation of H3K27 (39, 45). In addition, G9a has been shown to 
have activity against several non-histone proteins including itself 
(46) though the most well-studied aspect of G9a biology is the 
H3K9me2-dependent repression of gene expression. From genetic 
and biochemical studies, it is clear that G9a-dependent H3K9me2 
is associated with genomic regions that are expressed at low levels 
(21) but the mechanisms that regulate the dynamic methylation 
patterns mediated by G9a still remain unclear. Indeed, as G9a 
lacks a domain that would promote direct interaction with DNA 
or chromatin, G9a has to rely on the DNA-binding capacity of its 
interaction partners.
In ES cells, G9a-dependent H3K9me2 is linked to de novo 
DNA methylation (47, 48). DNA methylation of endogenous 
retroelements, and a subset of non-repetitive sequences includ-
ing CpG-rich promoters, is reduced in G9a-deficient cells, and 
Dnmt3a recruitment to retrotransposons is decreased in these 
cells. However, the interaction between G9a, H3K9me2, and 
DNMTs was absent in differentiated cells (48), suggesting that 
functional G9a–DNMT interactions are not maintained past 
development. Related to this function of G9a, the sustained silenc-
ing of pluripotency-associated genes in G9a-deficient ES cells is 
impaired and results in the reversal from the differentiated into 
a pluripotent state in a significant fraction of cells (49, 50). This 
effect has been exploited in the generation of induced pluripotent 
stem cells as inclusion of a G9a-specific chemical inhibitor BIX-
01298 can replace viral transduction of Sox2 in fibroblasts (51).
Taken together, a general theme of G9a playing a role in the 
epigenetic silencing of cell-type inappropriate genes has emerged 
from studies in ES cells (52, 53). However, the role of G9a in 
immune cell function is less well understood.
G9a CAN MeTHYLATe NON-HiSTONe 
PROTeiNS
In addition to its role as a histone lysine methyltransferase, sev-
eral studies have shown that G9a is also able to methylate a wide 
range of non-histone targets, including G9a itself (46), CDYL1, 
WIZ and ACINUS, C/EBPβ, CSB, histone deacetylase (HDAC)1, 
mAM, KLF12, SIRT1, Reptin, MyoD, p21, and p53 (54). Although 
the precise role of posttranslational methylation on protein 
function remains unclear, methylation of non-histone proteins 
may affect protein stability, protein–protein interactions, subcel-
lular localization, or function (55). Nevertheless, the precise 
physiological role of G9a-dependent methylation of non-histone 
proteins remains unclear and will not be discussed in depth in 
this review.
G9a HAS MeTHYLTRANSFeRASe-
iNDePeNDeNT ACTiviTieS
Apart from its ability to methylate substrates, G9a has also 
been shown to have methyltransferase-independent activities 
through the N-terminal domain of the G9a protein (35, 36, 38). 
Work from the Stallcup group was the first to show that in 
contrast to expectations, G9a was a strong coactivator of nuclear 
hormone receptor activity including androgen, estrogen, and 
glucocorticoid receptors by associating with the transcriptional 
coactivators GRIP1, CARM1, and p300 (35), and in the case of 
estrogen, with the receptor itself (36). G9a has also been shown 
to positively regulate gene expression at the β-globin gene locus 
(37). Regulation of the β-globin gene locus is a well-characterized 
system to examine the role of locus control regions (LCRs) in 
tissue- and stage-specific expression of genes (56). In red blood 
cells, the β-globin locus is regulated partially through the addi-
tion and removal of histone modifications including H3K4me3 
and H3K9me2 (57). Knockdown of G9a in adult erythroid 
progenitor cells led to the heightened mis-expression of fetal 
β-globin as well as a significant reduction in adult β-globin gene 
expression (37), further demonstrating inhibitory and activating 
effects of G9a. Similar to studies with nuclear hormone recep-
tors, the activation of gene expression by G9a was independent 
of methyltransferase activity. Importantly, the β-globin gene 
locus is regulated in a similar manner to the type 2 response 
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Il4-Il5-Il13 locus (58) and may provide a common mechanistic 
link to regulate gene expression. Thus, in addition to its repres-
sive functions, it is clear that G9a can positively influence gene 
expression at select genetic loci.
G9a iN THe iMMUNe SYSTeM
The vast majority of studies on the function of G9a have been car-
ried out in ES cells and very little is known about the role of G9a in 
innate and adaptive immune cells. However, the ability of immune 
cells to respond to the external environment and differentiate into 
functionally distinct cell lineages is reminiscent of the cellular 
plasticity of ES cells and suggests that epigenetic mechanisms 
may be a conserved regulatory mechanism in these cell types.
In innate immune cells such as macrophages, G9a-dependent 
H3K9me2 has been associated with gene repression during 
endotoxin tolerance (59–61). Macrophages that are chronically 
stimulated with lipopolysaccharide (LPS) become unresponsive 
to further LPS stimulation through the acquisition of H3K9me2 
at repressed genetic loci (61). In tolerized macrophages, G9a has 
been shown to interact with the TF ATF7 as well as several mem-
bers of the NF-κB family including RelB, RelA, c-Rel, and NF-κB1 
(59–61). It is proposed that G9a is recruited to specific loci by these 
factors to deposit H3K9me2, leading to gene repression. However, 
a direct role for G9a in macrophages during endotoxin tolerance 
has not been tested. Nevertheless, these studies identify a role for 
G9a in gene silencing during cellular responses to inflammatory 
signals. Consistent with this role in promoting tolerance, G9a 
has been also shown to limit JAK/STAT signaling in Drosophila 
following viral infections (62). In the absence of G9a, viral infec-
tion leads to increased lethality in flies but is not due to increased 
pathogen burden but due to heightened expression of JAK/STAT-
dependent target genes. Thus, G9a is an important regulator of 
innate inflammatory gene expression.
G9a has also been implicated in several aspects of T cell biol-
ogy. Although genome-wide studies mapping the binding of G9a 
or the deposition of H3K9me2 in immune cells has not been 
carried out due to technical reasons, a descriptive genome-wide 
analysis of H3K9me2 marks in resting human lymphocytes using 
ChIP-on-chip methods demonstrated that this epigenetic mark 
is enriched on genes that are associated with several specific 
pathways including T cell receptor signaling, IL-4 signaling, and 
GATA3 transcription (63). Furthermore, lymphocytes isolated 
from patients with type I diabetes displayed a distinct H3K9me2 
profile, with genetic regions that had increased (CXCL3, CTLA-4, 
SLC17A4) and reduced (RARA, CAMK4, TNF) levels of H3K9me2 
(64). Thus, G9a-mediated H3K9me2-dependent regulation of 
T cell responses may be associated with T cell function as well as 
development of inflammatory diseases such as diabetes.
More recently, cell lineage-specific deletion of G9a has been 
used to delineate the role of G9a in immune cells. Three independ-
ent strains of mice with a “floxed” G9a allele (G9afl/fl mice) have 
been generated (16, 65, 66). Crossing G9afl/fl mice with Cd4-Cre 
mice or Lck-Cre mice results in a T cell-specific deletion of G9a 
(G9aΔT mice). G9aΔT mice are born and develop normally and 
have no discernable defects in the generation of T  cells in the 
thymus, spleen, or lymph nodes (16, 67), suggesting that unlike 
ES cells G9a is dispensable for cellular development of peripheral 
naive T cells. However, upon activation of T cells in vitro or in vivo, 
G9a was shown to play a critical role in regulating the function of 
Th cells. Consistent with the ability of G9a to promote and repress 
gene expression, G9a-deficient Th cells had a failure to produce 
certain cytokines while overproducing others (15, 16). Under 
distinct differentiating conditions, G9a was differentially required 
to activate or repress specific gene programs.
Th1 cells that produce IFN-γ are critical for immunity against 
intracellular pathogens including bacteria, viruses, and proto-
zoan parasites (68). Strikingly, the absence of G9a in T cells has 
no effect on the development or magnitude of Th1 cell responses 
in vitro or in vivo (16). There was no difference in the frequency 
of Th1 cells that developed following activation of G9a-deficient 
T cells or wild type T cells in the presence of a G9a-specific inhibi-
tor under Th1  cell-promoting conditions (16). Thus, from our 
understanding so far, G9a is dispensable for Th1 cell responses.
Immunity to infection with parasitic helminths such as the 
whipworm Trichuris muris is associated with a polarized type 2 
cytokine response, with the production of IL-4, IL-5, and IL-13 
by Th cells leading to mucus production, intestinal epithelial 
cell turnover, and worm expulsion (69). Infection of G9aΔT mice 
with Trichuris resulted in significantly reduced frequencies of 
protective Th2 cells, heightened frequencies of non-protective 
Th1 cells, and susceptibility to infection (16). This was consistent 
with a reduction in the production of type II cytokines by Th cells 
after in vitro activation. A role for G9a in repressing promiscuous 
type I cytokine gene expression in Th2 cells was only observed 
temporarily, as H3K9me2 is replaced by H3K27me3 at the Ifng 
locus during differentiation (70). Thus, G9a is required for activa-
tion of the type II cytokine gene program. G9a-deficient Th2 cells 
express comparable levels of the major Th2 cell transcriptional 
factors including GATA3 and STAT6 but fail to produce type II 
cytokines, suggesting that G9a is a central component of the tran-
scriptional machinery for type II cytokines. As the Il4-Il5-Il13 
locus is similar in genetic structure to the β-globin locus, it is 
perhaps not surprising that the ability of G9a to transactivate the 
type II cytokine gene locus was also independent of its methyl-
transferase activity (16). Taken together, these results identify a 
role for G9a as a critical component of the Th2 cell regulatory 
machinery.
In contrast to Th2 cells, G9a plays an important role in limit-
ing Th17 and Treg cell differentiation that is dependent upon its 
methyltransferase activity (15). Activation of G9a-deficient Th 
cells under Th17- or Treg cell-promoting conditions resulted in 
a significant increase in the frequencies of IL-17A-producing and 
FOXP3-expressing cells, respectively (15). Inhibition of G9a meth-
yltransferase activity with the small-molecule inhibitors BIX-01294 
or UNC0638 also resulted in enhanced Th17 and Treg cell differ-
entiation. Unlike the proposed role for G9a in ES cells, H3K9me2 
is not deposited at lineage-promiscuous genes to control lineage 
differentiation in Th cells. Instead, G9a-dependent H3K9me2 is 
found at high levels in naive undifferentiated Th cells and is rapidly 
lost at lineage-specific and -non-specific loci after T cell activation 
(15). The loss of H3K9me2 alone is insufficient to promote gene 
expression, providing an explanation for the lack of a phenotype 
in the steady state. Thus, in naive T cells, H3K9me2 and G9a act 
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as an additional layer of negative regulation to maintain cells in 
a naive state. Mechanistically, loss of G9a-dependent H3K9me2 
results in an increase in the accessibility of the chromatin to 
transactivating factors, which leads to heightened responsiveness 
to external signals such as cytokines. In the case of Th17 and Treg 
cells, G9a-deficient Th cells are ~40 times more sensitive to TGF-β 
(15). Taken together, these results suggest that G9a, through the 
deposition of H3K9me2 at a wide variety of immune genes, is 
specifically important in naive T cells to repress gene expression, 
possibly by limiting accessibility of TFs and coactivators to specific 
genetic loci.
Unlike naive T cells, G9a has been proposed to repress expres-
sion of CD25 and CD27, cell surface receptors that are associated 
with cell activation and proliferation, in memory T cells during 
viral infection (71). Through a specific interaction with the tran-
scriptional repressor Blimp-1 (PRDM1), G9a (but not EZH2) is 
recruited to specific genetic loci resulting in gene repression. In 
the absence of Blimp-1, reduced levels of H3K9me2, H3K9me3, 
and H3K27me3 is observed, suggesting that G9a is critical for 
the silencing of genes during memory T cell differentiation and 
development. Whether G9a is required for memory T cell gen-
eration has not been examined directly; however, this is an active 
area of research, which will shed further light on the role of G9a 
in T  cell memory development. Thus, in the absence of G9a, 
other repressive modifications such as Suv39h1/2-dependent 
H3K9me3 and EZH2-dependent H3K27me3 may compensate. 
Although, the details remain unclear, the identification of the 
epigenetic mechanisms in memory T cell development and func-
tion will be critical for the optimal design of vaccines as well as 
the development of therapeutic strategies to target dysregulated 
memory T cell responses in inflammatory diseases.
In addition to T  cells, G9a also plays a critical role in the 
development and differentiation of ILCs (72). Mice with a 
hematopoietic cell-specific deletion of G9a (generated by crossing 
G9afl/fl mice with Vav-Cre mice) have reduced numbers of group 
2 ILCs (ILC2s) and increased frequencies of ILC3s in all tissues 
examined. Although the small number of ILC2s present in lung 
tissue are phenotypically normal, they are dysfunctional, failing 
to produce effector cytokines IL-5 and IL-13 following stimu-
lation with the activating cytokine IL-33 or following intranasal 
administration of the protease allergens papain or house dust mite 
antigen (72). Genome-wide expression analysis of bone marrow-
derived ILC2 precursors identified a global shift in expression 
from ILC2-specific transcripts to ILC3-specific genes, placing 
G9a and H3K9me2 as a central regulator of the ILC2/ILC3 lineage 
choice.
In contrast to T cells and ILCs, G9a appears to play a minor 
role in B cell development and function (52, 67). An early study 
using a V–D–J minilocus suggested that G9a inhibited germline 
transcription and recombination (73). However, mice with a 
B cell-specific deletion of G9a (Mb1-Cre) fail to show any overt 
phenotypes, including displaying normal V–D–J recombination 
(67). The absence of G9a did result in a skewed usage of the 
κ light chain over the λ light chain, as well as a slight reduction 
in IL-4- and LPS-induced proliferation and differentiation into 
plasma cells. This reduction in plasma cell differentiation is 
consistent with a study showing that G9a directly interacts with 
Blimp-1, a critical plasma cell differentiation factor (74). Thus, 
G9a is dispensable for normal B cell development and has little 
effect on most functions of B cells. However, it is possible that G9a 
has a subtle role in specific aspects of B cell biology that remain 
to be determined.
Together, these results demonstrate that G9a is an important 
regulator of immune cell function. However, the precise mecha-
nisms are yet to be defined. In the following sections, immune 
functions regulated by proteins known to interact with G9a 
will be discussed and potential mechanisms for G9a-dependent 
regulation will be proposed.
iNTeRACTiONS AND POTeNTiAL  
ROLeS OF G9a
From the studies outlined above, it is clear that G9a is a central 
regulatory node in the establishment of the epigenetic landscape 
of cells and is critical for shaping cellular identity. However, how 
G9a mediates its function is poorly understood. As G9a lacks a 
DNA-binding domain, it is dependent upon additional cofactors 
for its localization at specific genetic loci. Several classes of G9a-
interacting proteins have been identified (Figure 2). Strikingly, 
many of the G9a cofactors have important roles in immune cell 
development and function, potentially offering a mechanistic 
explanation for the phenotypes associated with loss of G9a in 
lymphoid cells.
Growth Factor independent 1
The transcriptional repressor growth factor independent 1 (Gfi1) 
is an important regulator of immune cell development and func-
tion (75). Gfi1 is able to bind to a large number of promoters and 
enhancers (76) and plays a central role in gene silencing through 
the recruitment of repressive modulators including histone 
methyltransferases, HDACs, and histone demethylases (77–79). 
Gfi1 has been shown to directly interact with G9a (78, 80) and 
Gfi1-deficient cells display a significant decrease in H3K9 methyl-
ation (78). Further, the phenotypes associated with Gfi1 deficiency 
in the immune system are strikingly similar to those observed 
in G9a-deficient mice, suggesting that Gfi1 is central to the 
function of G9a.
Gfi1 was first identified as a factor that, when induced or 
overexpressed in an IL-2-dependent T  cell line, led to IL-2-
independent growth (81). Furthermore, Gfi1 was shown to reduce 
the requirement for IL-2 by modulating the cell cycle regulation 
of T cells (82, 83). More recently, Gfi1 has been described to have 
multiple effects that echo the phenotypes seen in mice lacking 
G9a in T cells. First, Gfi1 is critical for promoting the differen-
tiation of Th2 cells through a variety of mechanisms including 
increasing GATA3 stability, enhancing Th2 cell proliferation, 
inhibiting Th1 cell differentiation, and promoting expression of 
type 2 cytokines (84–87). Under Th2 cell-polarizing conditions, 
Gfi1 was found to be highly upregulated by IL-4 in a STAT6-
dependent manner (84) and retroviral overexpression of Gfi1 in 
Th2 cells resulted in increased proliferation and survival (84). 
Gfi1-deficient T cells failed to optimally produce IL-4 after in vitro 
stimulation or following infection with the helminth parasite 
FiGURe 2 | The interactions of G9a. G9a interacts with a large number of proteins including NF-kB family members RelA, c-Rel, and RelB,  
as well as zinc finger E-box-binding (Zeb2), growth factor independent 1 (Gfi1), and Blimp-1.
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Schistosoma mansoni (87). Mechanistically, Gfi1 inhibits the 
proteasomal degradation of GATA3 through its N-terminal Snail/
Gfi1 (SNAG) domain (85). As Th2 cell differentiation is impaired 
in G9a-deficient T cells (16), it is possible that G9a–Gfi1–GATA3 
interactions are critical for the establishment of a transcriptional 
module that results in activation of the type 2 cytokine locus. 
Based on the role of the G9a N-terminus in activating nuclear 
hormone receptor-dependent gene expression by acting as scaf-
fold (38), these results suggest that in Th2 cells, the N-terminus 
of G9a may aid in recruitment of Gfi1, GATA3, and potentially 
other factors required for optimal Th2 cell development.
Growth factor independent 1 has also been implicated in the 
differentiation of Th17 and Treg cells (88). Downregulation of Gfi1 
expression by TGF-β is critical to allow expression of IL-17A/F 
in Th17  cells and CD103 in Treg cells (88) as well as surface 
expression of the ectonucleotidases CD39 and CD73 (89). Gfi1 
potentially recruits the lysine demethylase LSD1 to these genetic 
loci to reduce the activating methylation marks. Upon stimula-
tion with TGF-β, Gfi1 expression is reduced allowing optimal 
Th17 and Treg cell differentiation. Gfi1-deficient T cells display 
increased production of IL-17A and increased FOXP3 expression 
in response to TGF-β, which is identical to G9a-deficient T cells 
(15). Further, similar to the dysregulated expression of IL-17A 
observed in G9a-deficient Th2 cells (16), Gfi1 is required to 
silence IL-17A expression in Th2 cells (88). Thus, it is intriguing 
to hypothesize that Gfi1–G9a interactions are critical to restrain 
Th17 and Treg cell responses, linking transcriptional repression 
to epigenetic gene silencing.
Growth factor independent 1 is also an important regulator 
of ILC2 development and function (90). Expression of Gfi1 is 
correlated to the expression of the IL-33 receptor (Il1rl1, ST2) 
and GATA3. Loss of Gfi1 in ILC2s leads to impaired expres-
sion of GATA3 and an upregulation of IL-17A expression. This 
is reminiscent of the role of G9a in ILC biology, where G9a is 
required to repress ILC3-specific genes during ILC2 development 
(72). However, the effects of G9a and potentially Gfi1 appear to be 
dependent upon the methyltransferase-dependent gene repres-
sive effects unlike in T cells.
Taken together, these results suggest that G9a–Gfi1 interactions 
are critical for their functions in T cells and ILCs. Future studies 
defining the molecular basis for these interactions may provide 
novel therapeutics to inhibit dysregulated Th2 cell responses 
that are associated with diseases such as asthma and allergy.
Zinc Finger e-Box-Binding Protein 2
Zinc finger E-box-binding proteins (Zeb1 and Zeb2) are TFs that 
have primarily been associated with TGF-β-dependent epithelial– 
mesenchymal transition in tumor cells (91, 92). Zeb proteins 
repress expression of several epithelial genes such as E-cadherin 
through the recruitment of repressive molecules including 
C-terminal binding protein (CtBP) and components of the 
nucleosome remodeling deacetylase complex (NuRD) including 
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HDAC1. Recently, in a proteomic screen of G9a-interacting 
proteins in activated and endotoxin-tolerant macrophages, G9a 
was found to be strongly associated with components of several 
complexes that regulate chromatin structure including the Swi/
SNF complex, NuRD complex, and CtBP/CoREST complexes 
(61). In breast cancer cells, G9a was shown to be a component of a 
complex containing Zeb2 and the NuRD component MTA1 (93). 
Interestingly, this was a highly dynamic complex that switched 
between a GATA3/G9a/MTA3 complex with a Zeb2/G9a/MTA1 
complex that cross-regulated each other. A potential complex of 
G9a, Zeb2, and GATA3 that interacts with the NuRD complex 
may provide a molecular mechanism for how G9a, independent 
of its methyltransferase activity, regulates type 2 gene expres-
sion in Th2 cells. It is clear that nucleosome remodeling is an 
important aspect of type 2 cytokine expression (94, 95); however, 
the precise molecular mechanisms remain elusive. In addition, 
a direct role for Zeb2 in Th2 cell differentiation has not been 
evaluated.
Zinc finger E-box-binding protein has been shown to regulate 
the development of protective CD8 T cells during viral infection 
(96, 97). Following infection with lymphocytic choriomeningitis 
virus (LCMV), Zeb2 expression is induced in effector CD8 T cells 
that express the surface marker KLRG1 and produce IFN-γ. The 
upregulation of Zeb2 is dependent upon the TF T-bet (Tbx21) 
and expression of Zeb2 is critical for the terminal differentiation 
of effector CD8 T cells that are required for immunity to viral 
infection. As GATA3 has been implicated in CD8 T cell function 
(98, 99), it is possible that a Zeb2/G9a/GATA3 complex is critical 
for the function of CD8 T  cell function during viral infection. 
Further, as TGF-β has been shown to play an important role in 
shaping an effective CD8 T cell response and memory formation 
(100–103), and G9a is critical for regulating TGF-β responsive-
ness (15), the intersection of these pathways may prove important 
for defining the molecular mechanisms of T cell biology during 
infection.
NF-κB
The NF-κB family of TFs plays a central and critical role in 
all aspects of immune cell biology (104). Both, the canonical 
(c-Rel, p65/RelA, and p50/NF-κB1) and non-canonical (RelB 
and NF-κB2) family members have been shown to be important 
regulators of immune cell function (105, 106). In a proteomic 
screen for G9a-binding partners, it was found that several mem-
bers of the NF-κB family (RelB, c-Rel, RelA, and NF-κB1) are 
highly enriched for binding to G9a in macrophages (61), and 
RelB had been previously shown to associate with G9a during 
endotoxin tolerance, which was associated with gene silencing 
(59). In addition, the ankyrin repeats of GLP have been shown to 
directly recognize and bind to a monomethylated lysine residue 
in RelA, which directly links the G9a/GLP complex to attenuate 
cell proliferation and inflammatory responses in immunologi-
cally important genes such as Il1b and Tnfa (107). Together, these 
studies suggest that induction of NF-κB by LPS results in the 
recruitment of G9a and gene silencing, leading to endotoxin toler-
ance. Thus, under these circumstances, G9a-dependent dimeth-
ylation of H3K9 is important for gene repression during cellular 
activation.
In T  cells, NF-κB family members have been shown to be 
important for Treg cell development and function (108–113) as 
well as implicated in Th17 cell responses (114, 115). In the absence 
of c-Rel or RelA, thymic-derived natural Treg (nTreg) cells have a 
severe developmental defect and show reduced ability to suppress 
inflammatory responses. In contrast, the absence of G9a had no 
effect on nTreg cell development or function and the development 
of peripherally-activated Treg (pTreg) cells was enhanced in the 
absence of G9a (15). Thus, whether G9a/NF-κB interactions are 
required for Treg cell function is unclear.
However, the interaction between G9a and the non-canonical 
family member RelB may prove to be more important in T cell 
biology. Recently, RelB was shown to have an important function 
in limiting the development of Th17 cells (114). Costimulation 
of Th17  cells through OX40–OX40L interactions resulted in a 
significant reduction in IL-17A expression. This effect was medi-
ated by RelB-dependent recruitment of G9a to the Il17a locus, 
resulting in repression of Il17a expression. Further, in the absence 
of RelB, Th17 cells show reduced pathogenicity and inflammation 
in experimental autoimmune encephalomyelitis (EAE) (114). 
Thus, it is likely that RelB/G9a interactions, possibly downstream 
of OX40/OX40L signaling, are required for optimal development 
of Th17 cells.
It is clear that there is a significant interaction between NF-κB 
and G9a, although the precise molecular mechanisms in distinct 
immune cells are yet to be elucidated. Nevertheless, placing G9a 
in the context of NF-kB signaling suggests that there is a close 
relationship between inflammatory signal transduction path-
ways and the epigenetic machinery to control gene expression 
during an immune response.
Blimp-1
Blimp-1 (Prdm1) is a zinc finger protein which directly interacts 
with G9a and has been shown to be central to the development 
of immune responses. Blimp-1 is a transcriptional repressor that 
contains a non-catalytic PR domain that is related to the SET meth-
yltransferase domain, and a zinc-finger DNA-binding domain 
(74). In the absence of Blimp-1, mice develop a lethal multiorgan 
inflammatory disease caused by an accumulation of effector and 
memory T cells (116), thus making Blimp-1 an important regula-
tor of the adaptive immune response. Blimp-1 is also required for 
repression of Il2 transcription in T cells, resulting in an autoregula-
tory loop that controls immune responses (117, 118). In addition, 
Blimp-1 is crucial for the IL-27-dependent induction of IL-10 by 
Th1 cells (so-called Tr1 cells) following infection with Toxoplasma 
gondii or influenza A virus (119, 120). Moreover, Blimp-1 is 
critical for the development of terminally differentiated effector 
CD8 T cells (121) and controls the development of “exhausted” 
CD8 T cells during chronic viral infection (122). Thus, Blimp-1 
plays an important role in T cell-mediated immunity to infection.
In CD8 T  cells, Blimp-1 has been directly linked to G9a-
dependent H3K9me2-mediated repression (71). Following viral 
infection, Blimp-1 recruits G9a to repress expression of CD25 and 
CD27 and limit the expansion and proliferation of CD8 T cells. 
However, in addition to H3K9me2, G9a was also associated 
with increased levels of H3K9me3 and H3K27me3, modifica-
tions that are not mediated by G9a, suggesting that additional 
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methyltransferases were associated with Blimp-1 and involved 
in gene silencing during effector differentiation. Thus, in addition 
to G9a, other mechanisms are likely to be required for the repres-
sion of lineage non-specific genes in differentiating cells.
In Th cells, similar to results in G9aΔT mice (15), mice with 
a T cell-specific deletion of Blimp-1 have increased frequencies 
of Th17 cells in the intestinal mucosa (123). Furthermore, IL-23- 
induced Blimp-1 has been shown to be critical for the devel-
opment of inflammatory Th17  cells that are required for the 
pathogenesis of EAE (124). Thus, mice lacking Blimp-1 in T cells 
fail to develop EAE. Although it remains unknown whether 
Blimp-1 and G9a directly interact in CD4 T cells, it is not outra-
geous to suggest that G9a/Blimp-1 interactions may be critical for 
the development of pathogenic Th17 cells, and blockade of this 
interaction may provide a new therapeutic strategy to prevent 
inflammatory diseases associated with dysregulated Th17  cell 
responses.
iNHiBiTiON OF G9a ACTiviTY BY 
CHeMiCAL PROBeS
Currently, there are several chemical probes that specifically 
target the methyltransferase activity of G9a. BIX-01294 was first 
identified in a high-throughput screen (125) and was shown to 
bind to the SET domain of G9a and GLP in the peptide-binding 
site, preventing methylation (126). BIX-01294 was subsequently 
optimized through structure–activity relationships to generate 
UNC0224, UNC0321, and E72 that showed increased activity 
and specificity (127, 128). The further development of UNC0638 
and UNC0642 resulted in a potent, specific, stable, and cell-
permeable inhibitor of G9a (129). However, UNC0642 has poor 
pharmacokinetics for in  vivo use. More recently, an additional 
inhibitor of G9a that is unrelated to UNC0642, called A-366, was 
discovered through an independent high-throughput screen 
(130, 131). Treatment of mice with A-366 showed no overt 
toxicity and was able to reduce the growth of tumor xenografts 
(131). Thus, although A-366 has not been tested in the context 
of inflammatory disease, these results suggest that inhibition 
of G9a could prove to be a significant therapeutic strategy to 
modulate immune responses.
CONCLUDiNG ReMARKS
It is clear that G9a is a central control point in lymphoid cell 
development, differentiation, and function. Acting through its 
diverse binding partners, G9a can repress and activate gene pro-
grams associated with a wide variety of immune responses. As 
G9a has been shown to be amenable to drug inhibition, blocking 
the function of G9a may provide a new therapeutic modality to 
modulate a wide variety of inflammatory diseases. For example, 
both Blimp-1 and G9a are required to limit Th17 cell develop-
ment in a cell-intrinsic manner (15, 123). However, the increased 
frequency of Th17 cells does not result in enhanced pathogenicity 
of inflammatory diseases such as EAE or intestinal inflammation 
(15, 124), demonstrating that reducing the activity of Blimp-1 or 
G9a, or by inhibiting their interaction, may be a viable method 
to reduce the development of pathogenic Th17  cells. Future 
studies will define the precise role of G9a in immune cell develop-
ment, differentiation, and function and determine the relevance 
of G9a as a drug target to treat inflammatory disease.
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